Amelie Harle Discusses Aprepitant for Cough in Lung Cancer
Amelie Harle, MD, PhD, an oncologist at the Christie Hospital in Manchester, United Kingdom, discusses aprepitant (Emend) to reduce cough in patients with lung cancer.
Amelie Harle, MD, PhD, an oncologist at the Christie Hospital in Manchester, United Kingdom, discusses aprepitant (Emend) to reduce cough in patients with lung cancer.
In a recent study, Harle and other researchers explored the NK-1 pathway, which has shown to be relevant to cough in five different species of animals. Centrally acting NK-1 antagonists had not previously been tested as novel antitussive agents in humans.
Cough was measured using recordings as well as questionairres, and findings showed that aprepitant significantly reduced cough in patients with lung cancer.
FDA Approves Amivantamab-Chemo Combo for Advanced NSCLC
September 19th 2024The FDA approved amivantamab-vmjw plus chemotherapy for locally advanced or metastatic non–small cell lung cancer (NSCLC) that harbors EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.
